ArticleEuropean heart journal. Case reports2025
Femoral vein occlusion after VASCADE MVP resolved without surgery: a case report.
Article in European heart journal. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: VASCADE MVP® is a vascular closure device developed to achieve haemostasis of large-bore venous access by deploying a collagen patch in the subcutaneous tissue. While its efficacy and safety have been demonstrated, venous occlusion has not been previously reported. Case summary: A 72-year-old woman was hospitalized and underwent pulmonary vein isolation for symptomatic paroxysmal atrial fibrillation. Two femoral venous sheaths (10-Fr and 8.5-Fr) were inserted under ultrasound guidance, and haemostasis was achieved using VASCADE MVP Venous Vascular Closure devices. On postoperative day 9, right leg swelling appeared. Contrast-enhanced CT showed stenosis of the right common femoral vein (CFV), and duplex ultrasound revealed a hyperechoic structure distal to the stenosis. Since deep vein thrombosis was suspected, the apixaban dose was adjusted from 10 to 20 mg/day. Due to persistent symptoms, venography was performed on Day 15, which revealed complete CFV occlusion. Intravascular endoscopy revealed white intraluminal material consistent with residual collagen, and subsequent balloon angioplasty led to partial restoration of blood flow. Given the gradual improvement in symptoms, conservative management was pursued, leading to complete recovery at 2 months as confirmed by duplex ultrasound. Discussion: This is the first reported case of venous occlusion likely caused by residual collagen from a collagen-based venous closure device. Balloon angioplasty restored partial blood flow, and surgical intervention was avoided due to the identification of collagen-induced reversible mechanical obstruction. When using VASCADE MVP, operators should be mindful to avoid intravascular deployment of collagen by ensuring proper technique.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.